3

Exemestane's 17-hydroxylated metabolite exerts biological effects as an androgen

^{1 1}Robert H. Lurie Comprehensive Cancer Center, Northwestern University Feinberg School of Medicine, Chicago, Illinois; ²Fox Chase Cancer Center, Philadelphia, Pennsylvania; and ³Division of Biocomputing, University of New Mexico Health Sciences Center, Albuquerque, New Mexico

^* To whom correspondence should be addressed. E-mail: v.craig.jordan{at}fccc.edu.

	Abstract

Aromatase inhibitors (AI) are being evaluated as long-term adjuvant therapies and chemopreventives in breast cancer. However, there are concerns about bone mineral density loss in an estrogen-free environment. Unlike nonsteroidal AIs, the steroidal AI exemestane may exert beneficial effects on bone through its primary metabolite 17-hydroexemestane. We investigated 17-hydroexemestane and observed it bound estrogen receptor (ER) very weakly and androgen receptor (AR) strongly. Next, we evaluated 17-hydroexemestane in MCF-7 and T47D breast cancer cells and attributed dependency of its effects on ER or AR using the antiestrogen fulvestrant or the antiandrogen bicalutamide. 17-Hydroexemestane induced proliferation, stimulated cell cycle progression and regulated transcription at high sub-micromolar and micromolar concentrations through ER in both cell lines, but through AR at low nanomolar concentrations selectively in T47D cells. Responses of each cell type to high and low concentrations of the non-aromatizable synthetic androgen R1881 paralleled those of 17-hydroexemestane. 17-Hydroexemestane down-regulated ER protein levels at high concentrations in a cell type–specific manner similarly as 17-estradiol, and increased AR protein accumulation at low concentrations in both cell types similarly as R1881. Computer docking indicated that the 17-OH group of 17-hydroexemestane relative to the 17-keto group of exemestane contributed significantly more intermolecular interaction energy toward binding AR than ER. Molecular modeling also indicated that 17-hydroexemestane interacted with ER and AR through selective recognition motifs employed by 17-estradiol and R1881, respectively. We conclude that 17-hydroexemestane exerts biological effects as an androgen. These results may have important implications for long-term maintenance of patients with AIs. [Mol Cancer Ther 2007;6(11):OF1–11]

Key Words: Breast cancer, exemestane, bone mineral density, androgen receptor, estrogen receptor, molecular modeling

This article has been cited by other articles:

				W. R. Miller, J. Bartlett, A. M. H. Brodie, R. W. Brueggemeier, E. di Salle, P. E. Lonning, A. Llombart, N. Maass, T. Maudelonde, H. Sasano, et al. Aromatase Inhibitors: Are There Differences Between Steroidal and Nonsteroidal Aromatase Inhibitors and Do They Matter? Oncologist, August 1, 2008; 13(8): 829 - 837. [Abstract] [Full Text] [PDF]